Serratia marcescens harboring SME-4 in Brazil: A silent threat

Cayô, Rodrigo; Leme, Ricardo José de Almeida; Streling, Ana Paula; Matos, Adriana Pereira; Nodari, Carolina Silva; Chaves, Jéssica Reis Esteves; Brandäo, Jorge Luiz Ferreira; Almeida, Maíra Fernandes de; Carrareto, Valério; Pereira, Marco Aurélio de Castro; Almeida, Jean Pierre Aquino de; Ferreira, Demian Candido; Gales, Ana Cristina

doi:10.1016/j.diagmicrobio.2017.01.008

Cited by 15 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This bacterium is an important opportunistic pathogen associated with serious infections. Recently, in Brazil, Cayô et al 30 reported an outbreak of septic shock associated with this strain. S. marcescens has been isolated from frozen shrimp and fish and may be associated with fish deterioration 31 .…”

Section: Discussionmentioning

confidence: 99%

Drug resistance, AmpC-β-lactamase and extended-spectrum β-lactamase-producing Enterobacteriaceae isolated from fish and shrimp

Almeida

Cangussú

Carvalho³

et al. 2017

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

The present study aims to detect the production of extended-spectrum beta-lactamases (ESBL) by enterobacteria isolated from samples of fresh shrimp and fish obtained from the retail trade of the city of Sobral, Ceará State, Brazil. All bacterial isolates were submitted to identification and antimicrobial susceptibility testing using aminopenicillin, beta-lactamase inhibitors, carbapenem, 1st, 2nd, 3rd and 4th generation cephalosporins, and monobactam. Three types of beta-lactamases - ESBL, AmpC and KPC - were investigated. 103 strains were identified, and the most frequent species in shrimp and fish samples was Enterobacter cloacae (n = 54). All the strains were resistant to penicillin and more than 50% of the isolates were resistant to ampicillin and cephalothin. Resistance to three 3rd generation cephalosporins (cefotaxime, ceftriaxone and ceftazidime) and one fourth generation cephalosporin (cefepime) was detected in two isolates of E. cloacae from shrimp samples. Phenotypic detection of AmpC was confirmed in seven strains. The ESBL was detected in two strains of E. cloacae from shrimp samples. No strain showed KPC production. These data can be considered alarming, since food (shrimp and fish) may be carriers of enterobacteria resistant to drugs of clinical interest.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug resistance, AmpC-β-lactamase and extended-spectrum β-lactamase-producing Enterobacteriaceae isolated from fish and shrimp

Almeida

Cangussú

Carvalho³

et al. 2017

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

show abstract

“…T he Serratia marcescens enzyme (SME) is an Ambler class A carbapenemase that was first identified in 1982 from two clinical S. marcescens strains in England (1) and has since been reported elsewhere in Europe (2,3), North America (4-6), and South America (7,8). Although the prevalence of SME-producing S. marcescens currently appears low, it is likely underestimated because none of the commercially available carbapenemase detection methods include bla SME (9).…”

mentioning

confidence: 99%

Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens

Biagi

Shajee

Vialichka

et al. 2020

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The Serratia marcescens enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3, 0, and 4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.

show abstract

“…This problem has already been emphasized in some countries, including Brazil. 6,7 Third, PMB resistance does occur without carbapenem resistance, 8 and this "silent resistance" is a concern because PMB is often used in clinical practice against those CRE. Fourth, although a small number of isolates was detected in this study, Enterobacter species are important in the acquisition of PMB resistance; they have been cited as a second epidemic agent emerging after the wave of a KPC-Kp.…”

mentioning

confidence: 99%

What’s Lurking Around the Corner? Polymyxin B Resistance Among Klebsiella pnemoniae carbapenemase–producing Enterobacteriaceae, and Others, as a Burden of Use

Perez

2017

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

Serratia marcescens harboring SME-4 in Brazil: A silent threat

Cited by 15 publications

References 6 publications

Drug resistance, AmpC-β-lactamase and extended-spectrum β-lactamase-producing Enterobacteriaceae isolated from fish and shrimp

Drug resistance, AmpC-β-lactamase and extended-spectrum β-lactamase-producing Enterobacteriaceae isolated from fish and shrimp

Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens

What’s Lurking Around the Corner? Polymyxin B Resistance Among Klebsiella pnemoniae carbapenemase–producing Enterobacteriaceae, and Others, as a Burden of Use

Contact Info

Product

Resources

About